1Bloss JD, Liao SY, Buller RE, et al. Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary[J]. Gynecol Oncol, 1993,50(3) :347 - 351.
2Lauehlan SC. The secondary Mullerian system revisited[J]. Int J Gynecol Pathol, 1994,13 ( 1 ) : 73 - 79.
3Pickartz H. Differential diagnosis of peritoneal lesions of Mullerian type and similar epithelial tumors of the peritoneum [J]. Int J Gynecol Pathol,1993,12(2):116-119.
4Wang PH, Liu RS, Li YF, et al. Whole-body PET with ( fluorine- 18 ) -2-deoxyglucose for detecting recurrent primary serous peritoneal carcinoma: An initial report[J]. Gynecol Oncol, 2000,77(1):44 -47.
5Altaras MM, Aviram R, Cohen I, et al. Primary peritoneal papillary serous adenocarcinoma: clinical and management aspects[J]. Gynecol Oncol, 1991,40(3) :230 - 236.
6Killackey MA, Davis AR. Papillary serous carcinoma of the peritoneal surface: matched-case comparison with papillary serous ovarian carcinoma[J]. Gynecol Onco1,1993,51(2): 171 - 174.
7Ben-Baruch G, Sivan E, Moran O, et al. Primary peritoueal serous papillary carcinoma: a study of 25 cases and comparison with stage Ⅲ - Ⅳ ovarian papillary serous carcinoma [ J ]. Gynecol Oncol, 1996,60 (3) : 393 - 396.
8Zhou J, Iwasa Y, Konishi I, et al. Papillary serous carcinoma of the peritoneum in women. A clinicopathologic and immunohistochemical study[J]. Cancer, 1995, 76(3) : 429 -436.
9Ichimura T, Ishiko O, Nishimura S, et al. Primary peritoneal clear cell carcinoma: excellent results from paclitaxel and carboplatin combination chemotherapy[J]. Oncol Rep, 2001,8 (6): 1243 - 1245.
10Garamvoelgyi E, Guillou L, Gebhard S, et al. Primary malignant mixed Mullerian tumor of the female peritoneum: A clinical, pathologic, and immunohistochemical study of 3 cases and a review of the literature[J]. Cancer, 1994,74(3 ): 854 - 863.
3Lauchlan S. The secondary mullerian system revisited. Int J Gynecol Pathol, 1994,13:73-79.
4Chen LM, Yamada S, Fu YS, et al. Molecular similarities between primary peritoneal and primary ovarian carcinomas. Int J Gynecol Cancer, 2003, 13 : 749-755.
5Khalifeh I, Munkarah A, Lonardo F, et al. Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma. Int J Gynecologic Pathol, 2004, 23:162-169.
6Altaras MM, Bernheim J, Zehavi T, et al. Papillary serous carcinoma of the peritoneum coexisting with or after endometrial carcinoma. Gynecol Oncol, 2002, 84:245-251.
7Ordonez NG. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol, 1998,22:1203-1214.
8Bloss JD, Brady MK, Liao SY, et al. Extraovarian peritoneal serous papillary carcinoma: a phase Ⅱ trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma-a Gynecologic Oncology Group study. Gynecol Oncol, 2003, 89 : 148-154.
9Swerdlow M. Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma of the ovary[J]. Am J Obstet Gynecol, 1959,77(1) : 197 - 200.
10Lauchlan SC. The secondary Mullerian system revisited [ J ]. Int J Gynecol Pathol, 1994,13( 1 ) : 73 - 79.
